Thurston, Springer, Miller, Herd & Titak, Inc. Moderna, Inc. Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $330 Million
- Q3 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Moderna, Inc. stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 111 shares of MRNA stock, worth $4,487. This represents 0.0% of its overall portfolio holdings.
Number of Shares
111
Previous 111
-0.0%
Holding current value
$4,487
Previous $13,000
46.15%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding MRNA
# of Institutions
953Shares Held
240MCall Options Held
10.6MPut Options Held
18.7M-
Baillie Gifford & CO42.5MShares$1.72 Billion2.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.2MShares$1.63 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY25.6MShares$1.03 Billion0.07% of portfolio
-
State Street Corp Boston, MA16.8MShares$681 Million0.05% of portfolio
-
Theleme Partners LLP London, X07.23MShares$292 Million28.47% of portfolio
About Moderna, Inc.
- Ticker MRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 391,200,000
- Market Cap $15.8B
- Description
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...